Drug name: Rapamycin + Paclitaxel


Related CSCTT Targets

Gastric cancer SP cells [ref.1]

Rapamycin

Cas.no PubChem ID
53123-88-9 5284616
Known Target
Serine/threonine-protein kinase mTORP42345
Peptidyl-prolyl cis-trans isomerase FKBP1AP62942
Fibroblast growth factor 2P09038
Structure
...
Introduction
Rapamycin was used as a kind of original antifungal antibiotic, which is produced by Streptomyces hygroscopicus. Now it has been used in the prevention of transplant rejection because of its immunosuppressive effect. It also exhibits activity against several transplantable tumors and slightly activity to inactive against leukemias. The immunosuppressive effect of Rapamycin is exerted by inhibiting the activation and proliferation of T cells. Rapamycin binds to FK-binding protein 12 (FKBP12) and forms the rapamycin-FKBP12 complex, which regulates an enzyme that plays an important role in the progression of the cell cycle. Rapamycin was confirm to be the inhibitor of mTOR.

Paclitaxel

Cas.no PubChem ID
33069-62-4 36314
Known Target
Tubulin beta-1 chainQ9H4B7
Apoptosis regulator Bcl-2P10415
Nuclear receptor subfamily 1 group I member 2O75469
Microtubule-associated protein 4P27816
Microtubule-associated protein 2P11137
Microtubule-associated protein tauP10636
Structure
...
Introduction
Paclitaxel is a mitotic inhibitor used in cancer chemotherapy. Paclitaxel is approved for ovarian, breast and lung, bladder, prostate, melanoma, esophageal, and other types of solid tumor cancers as well as Kaposi's sarcoma.

Reference

  • [1] A c-Met inhibitor increases the chemosensitivity of cancer stem cells to the irinotecan in gastric carcinoma. Yashiro, M., et al. (2013).Br J Cancer. 109(10):2619-28.
    24129235. [ 24129235 ]

Back to top